Literature DB >> 31730015

Diffusion-weighted imaging for identifying patients at high risk of tumor recurrence following liver transplantation.

Yi-Hsuan Chuang1, Hsin-You Ou1, Chun-Yen Yu1, Chao-Long Chen2, Ching-Chun Weng1, Leo Leung-Chit Tsang1, Hsien-Wen Hsu1, Wei-Xiong Lim1, Tung-Liang Huang1, Yu-Fan Cheng3.   

Abstract

BACKGROUND: Tumor recurrence is the major risk factor affecting post-transplant survival. In this retrospective study, we evaluate the prognostic values of magnetic resonance (MR) diffusion-weighted imaging (DWI) in liver transplantation for hepatocellular carcinoma (HCC).
METHODS: From April 2014 to September 2016, 106 HCC patients receiving living donor liver transplantation (LDLT) were enrolled. Nine patients were excluded due to postoperative death within 3 months and incomplete imaging data. The association between tumor recurrence, explant pathologic findings, and DWI parameters was analyzed (tumor-to-liver diffusion weighted imaging ratio, DWIT/L; apparent diffusion coefficients, ADC). The survival probability was calculated using the Kaplan-Meier method.
RESULTS: Sixteen of 97 patients (16%) developed tumor recurrence during the follow-up period (median of 40.9 months; range 5.2-56.5). In those with no viable tumor (n = 65) on pretransplant imaging, recurrence occurred only in 5 (7.6%) patients. Low minimum ADC values (p = 0.001), unfavorable tumor histopathology (p <  0.001) and the presence of microvascular invasion (p <  0.001) were risk factors for tumor recurrence, while ADCmean (p = 0.111) and DWIT/L (p = 0.093) showed no significant difference between the groups. An ADCmin ≤ 0.88 × 10- 3 mm2/s was an independent factor associated with worse three-year recurrence-free survival (94.4% vs. 23.8%) and overall survival rates (100% vs. 38.6%).
CONCLUSIONS: Quantitative measurement of ADCmin is a promising prognostic indicator for predicting tumor recurrence after liver transplantation.

Entities:  

Keywords:  ADC value; Diffusion weighted imaging; Tumor recurrence

Year:  2019        PMID: 31730015     DOI: 10.1186/s40644-019-0264-y

Source DB:  PubMed          Journal:  Cancer Imaging        ISSN: 1470-7330            Impact factor:   3.909


  5 in total

1.  The Roles of Diffusion Kurtosis Imaging and Intravoxel Incoherent Motion Diffusion-Weighted Imaging Parameters in Preoperative Evaluation of Pathological Grades and Microvascular Invasion in Hepatocellular Carcinoma.

Authors:  Fei Wang; Chun Yue Yan; Cai Hong Wang; Yan Yang; Dong Zhang
Journal:  Front Oncol       Date:  2022-05-11       Impact factor: 5.738

Review 2.  Diffusion-Weighted Imaging Reflects Tumor Grading and Microvascular Invasion in Hepatocellular Carcinoma.

Authors:  Alexey Surov; Maciej Pech; Jazan Omari; Frank Fischbach; Robert Damm; Katharina Fischbach; Maciej Powerski; Borna Relja; Andreas Wienke
Journal:  Liver Cancer       Date:  2021-01-27       Impact factor: 11.740

3.  Prognostic value of baseline imaging and clinical features in patients with advanced hepatocellular carcinoma.

Authors:  Osman Öcal; Michael Ingrisch; Muzaffer Reha Ümütlü; Bora Peynircioglu; Christian Loewe; Otto van Delden; Vincent Vandecaveye; Bernhard Gebauer; Christoph J Zech; Christian Sengel; Irene Bargellini; Roberto Iezzi; Alberto Benito; Maciej Pech; Peter Malfertheiner; Jens Ricke; Max Seidensticker
Journal:  Br J Cancer       Date:  2021-10-22       Impact factor: 7.640

Review 4.  Patient Selection for Downstaging of Hepatocellular Carcinoma Prior to Liver Transplantation-Adjusting the Odds?

Authors:  Daniel Seehofer; Henrik Petrowsky; Stefan Schneeberger; Eric Vibert; Jens Ricke; Gonzalo Sapisochin; Jean-Charles Nault; Thomas Berg
Journal:  Transpl Int       Date:  2022-04-21       Impact factor: 3.842

5.  A Scoring System for Predicting Microvascular Invasion in Hepatocellular Carcinoma Based on Quantitative Functional MRI.

Authors:  Chien-Chang Liao; Yu-Fan Cheng; Chun-Yen Yu; Leung-Chit Leo Tsang; Chao-Long Chen; Hsien-Wen Hsu; Wan-Ching Chang; Wei-Xiong Lim; Yi-Hsuan Chuang; Po-Hsun Huang; Hsin-You Ou
Journal:  J Clin Med       Date:  2022-06-30       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.